Participation in another trial within 30 days prior to enrolment

Gravidity (pregnancy test prior to each treatment cycle)

Intake of omalizumab

Hepatitis or HIV or malignant disease

Specific immunotherapy in the last 6 months

Non-allergic asthma

Auto-immune diseases

Hypocalcaemia

Intake of ACE-inhibitors (discontinuation according to half-time before treatment possible)

Uncontrolled bleeding and coagulation disorders

Severe cardiovascular disease

Severe cardiac arrhythmias

Severe systemic infection

Unability to tolerate therapeutic apheresis procedures (hypersensitivity associated with previous apheresis sessions)

Inadequate peripheral venous access

Condition in which acute fluid shifts may cause congestive heart failure

Established or suspected intra-cranial disease where fluid imbalance or pressure changes could exacerbate the disease

Impaired renal function

Clinically significant hypotension or borderline hypotension where a further drop in blood pressure could be harmful

Extracorporeal SPecific IgE Removal From the Plasma of Allergic Asthma Patients (ESPIRA-study)